Scarica l'app Stockscreener
4.31
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.31
Aprire:
$4.31
Volume 24 ore:
225.72K
Relative Volume:
0.21
Capitalizzazione di mercato:
$299.20M
Reddito:
-
Utile/perdita netta:
$-98.79M
Rapporto P/E:
-1.318
EPS:
-3.27
Flusso di cassa netto:
$-51.66M
1 W Prestazione:
+1.89%
1M Prestazione:
+6.16%
6M Prestazione:
+606.56%
1 anno Prestazione:
+945.10%
Intervallo 1D:
$4.08
$4.4499
Intervallo di 1 settimana:
$4.045
$4.49
Portata 52W:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Confronta RLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
3.6399 | 4.84B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.25 | 431.07M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.76 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.955 | 369.04M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.66 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | Jefferies | Buy |
| 2025-11-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Australia
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
FDA backs new bladder cancer studies for patients with few options left - Stock Titan
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - ulpravda.ru
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - ulpravda.ru
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Corient Private Wealth LLC Invests $120,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Small Cap Biotech In 2025: Winning Pivots And Zombie Killers - Citeline News & Insights
Relmada’s BOOST Phase 3 Bladder Cancer Trial Sets Up a New Catalyst for RLMD Investors - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Update - Defense World
Jefferies Financial Group Begins Coverage on Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of Relmada Therapeutics (RLMD) with Buy Recommendation - Nasdaq
Relmada Therapeutics (RLMD) Initiates Coverage with Buy Rating | RLMD Stock News - GuruFocus
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Treasury Yields: Is NEHC stock recession proof2025 Trading Recap & Weekly Stock Breakout Alerts - moha.gov.vn
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot - Investing.com Nigeria
Jefferies initiates Relmada Therapeutics stock with Buy rating on pipeline pivot By Investing.com - Investing.com South Africa
Jefferies Starts Relmada Therapeutics Inc (RLMD) at Buy - StreetInsider
Inflation Data: Will Las Vegas Sands Corp stock outperform value peersPortfolio Return Summary & Real-Time Market Sentiment Reports - moha.gov.vn
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Product Launch & Entry Point Confirmation Signals - Улправда
Is Relmada Therapeutics Inc. stock supported by strong cash flowsPortfolio Growth Summary & Entry Point Confirmation Alerts - Улправда
Why Relmada Therapeutics Inc. stock remains undervalued2025 Buyback Activity & Real-Time Buy Zone Alerts - Улправда
Momentum Shift: Why Relmada Therapeutics Inc. (4E2) stock benefits from AI revolution2025 Performance Recap & Low Risk Growth Stock Ideas - Улправда
Recap Report: Is Relmada Therapeutics Inc. stock supported by strong cash flowsBond Market & AI Enhanced Trading Alerts - Улправда
How Relmada Therapeutics Inc. (4E2) stock moves in volatile trading sessions2025 Trade Ideas & Free Expert Verified Stock Movement Alerts - Улправда
Is Relmada Therapeutics Inc. stock supported by innovation pipeline2025 Market Trends & Reliable Intraday Trade Alerts - Улправда
Have you been able to find a good deal on Relmada Therapeutics Inc’s shares? - uspostnews.com
RelmadaA New Contender To Watch In Bladder Cancer Drug Development? - RTTNews
Maged Shenouda Increases Stake in Relmada Therapeutics Inc (RLMD) - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) CFO Buys $48,059.80 in Stock - MarketBeat
Relmada Therapeutics updates executive contracts and increases salaries By Investing.com - Investing.com Australia
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relmada Therapeutics Inc Azioni (RLMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
1.88%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):